Journal article · 2025 · Open access

Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients

Xiaohang Qian, Si‐Yue Chen, Pei‐Jing Cui, Miao Zhang, H Tang

Alzheimer s & Dementia, 21(S7), e108511 · Published 1 December 2025 · DOI 10.1002/alz70861_108511

Open PDFView at the publisherCite this paper

In brief

“Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients” is a 2025 journal article by Xiaohang Qian and 4 co-authors, published in Alzheimer s & Dementia. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY licence: the full text is free to read at Alzheimer s & Dementia.

Citations
0
Authors
5

Abstract

BACKGROUND: Anti-Amyloid β (Aβ) immunotherapy has been shown to clear Aβ and delay cognitive decline in Alzheimer's disease (AD). Recent studies suggest that the efficacy of this treatment is linked to microglial activation. However, direct evidence from cohort studies is lacking. The 18-kDa translocator protein (TSPO)-positron emission tomography (PET) imaging allows for in vivo assessment of microglial activation. METHOD: The study included 10 early AD patients ((i.e., mild cognitive impairment or mild AD) treated with Lecanemab monoclonal antibody (10 mg/kg, biweekly) for 12 months, and 7 untreated early AD patients as controls. All participants underwent Aβ (AV45) and TSPO (DPA714) PET scans and cognitive tests at baseline and after 12 months. RESULT: No significant demographic differences were found between the Lecanemab and control groups. Both groups had similar proportions of APOE4-positive individuals, cognitive levels, Aβ load, and microglial activation. At 12 months, the Lecanemab group showed a -0.34 SUVR for AV45/PET and a +0.05 SUVR for DPA714/PET. Correlation analysis revealed a positive correlation between increased frontal (r=-0.59, p =0.023) and temporal (r=-0.59, p =0.023) DPA714 SUVR levels and decreased AV45 SUVR levels. Additionally, an increase in parietal DPA714 SUVR was negatively correlated with MMSE score reduction (r=-0.53, p =0.04). CONCLUSION: Microglial activation plays a crucial role in the efficacy of Anti-Aβ immunotherapy, promoting Aβ clearance and delaying cognitive decline.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Qian, X., Chen, S., Cui, P., Zhang, M., & Tang, H. (2025). Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients. Alzheimer s & Dementia, 21(S7), e108511. https://doi.org/10.1002/alz70861_108511

MLA 9

Qian, Xiaohang, et al. “Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients.” Alzheimer s & Dementia, vol. 21, no. S7, 2025, p. e108511. https://doi.org/10.1002/alz70861_108511.

Chicago

Qian, Xiaohang, Si‐Yue Chen, Pei‐Jing Cui, Miao Zhang, and H Tang. 2025. “Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients.” Alzheimer s & Dementia 21 (S7): e108511. https://doi.org/10.1002/alz70861_108511.

Harvard

Qian, X. et al. (2025) ‘Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients’, Alzheimer s & Dementia, 21(S7), p. e108511. doi:10.1002/alz70861_108511.

IEEE

X. Qian, S. Chen, P. Cui, M. Zhang, and H. Tang, “Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients,” Alzheimer s & Dementia, vol. 21, no. S7, p. e108511, 2025, doi: 10.1002/alz70861_108511.

BibTeX

@article{qian2025microglial,
  title     = {{Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients}},
  author    = {Qian, Xiaohang and Chen, Si‐Yue and Cui, Pei‐Jing and Zhang, Miao and Tang, H},
  journal   = {Alzheimer s \& Dementia},
  year      = {2025},
  volume    = {21},
  number    = {S7},
  pages     = {e108511},
  doi       = {10.1002/alz70861_108511},
  url       = {https://doi.org/10.1002/alz70861_108511}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • microglial activation
  • lecanemab

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Qian, X., Chen, S., Cui, P., Zhang, M., & Tang, H. (2025). Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab‐Treated Early AD Patients. Alzheimer s & Dementia, 21(S7), e108511. https://doi.org/10.1002/alz70861_108511

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Alzheimer s & Dementia: sign in and open the PDF from this page.

Who wrote this paper?

Xiaohang Qian, Si‐Yue Chen, Pei‐Jing Cui, Miao Zhang, H Tang.

What is the DOI of this paper?

10.1002/alz70861_108511, permanently at https://doi.org/10.1002/alz70861_108511. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.